title: The therapeutic potential of immuno-cell therapy of cancer in combination with aminobisphosphonates.
abstract: Many university hospitals and cancer centers in Japan have actively investigated the use of autologous activated lymphocyte therapy (ALT). However its therapeutic efficacy was found to be quite limited. The efficacy of aminobisphosphonates (aBPs) has been shown for osteolytic bone disease. aBPs could activate and induce the proliferation of gamma/delta (gamma/delta) T-cells. The application of aBPs to ALT in vivo or ex vivo may be beneficial. A brief overview of aBPs and gamma/delta T-cells is provided, together with some preliminary results and discussion of the therapeutic potential of ALT in combination with aBPs.
authors.affiliation: Seta Clinic, Setagaya-ku, Tokyo. goto@j-immunother.com
authors.forename: Shigenori
authors.initials: S
authors.lastname: Goto
authors.forename: Atsutaka
authors.initials: A
authors.lastname: Noguchi
authors.forename: Hidemasa
authors.initials: H
authors.lastname: Jinguji
authors.forename: Masashi
authors.initials: M
authors.lastname: Takahara
mesh_terms: D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D004164:Diphosphonates; D016692:Receptors, Antigen, T-Cell, gamma-delta